Rhelion Life Sciences Corp.
RHEL
CNSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -86.68% | -62.41% | -104.07% | 17.03% | 62.39% |
| Total Depreciation and Amortization | -25.23% | -62.52% | -58.10% | -54.55% | -75.47% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 405.25% | 1,199.47% | 17,441.67% | 33.96% | -84.91% |
| Change in Net Operating Assets | -6.75% | -106.92% | 102.47% | -59.68% | 53.18% |
| Cash from Operations | 13.33% | -234.42% | 38.68% | -28.67% | 32.26% |
| Capital Expenditure | 93.80% | 91.64% | 73.13% | 70.55% | 83.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -5,452.38% | -- | -- | -100.00% |
| Cash from Investing | -168.61% | -870.51% | -4,941.79% | 23.81% | 81.87% |
| Total Debt Issued | -875.88% | -- | -- | -99.12% | -- |
| Total Debt Repaid | -150.60% | 60.41% | 50.15% | -1,136.58% | 193.83% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -385.85% | 339.96% | 50.50% | -233.90% | 205.82% |
| Foreign Exchange rate Adjustments | -101.14% | -1,118.75% | 164.74% | 569.57% | 449.60% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.75% | -296.81% | 9.35% | -460.08% | 59.38% |